Treatment evaluation of combined modality therapy: 'what can we obtain today from phase II trials?'.
AffiliationChristie Hospital, CRC Department of Medical Oncology, Manchester, UK.
MetadataShow full item record
AbstractDemonstration of activity is the major goal of Phase II studies. Other end points-duration of response, survival (relapse free in complete responders), progression free interval, changes in performance status and quality of life also provide useful information. From these data a decision to continue or discard a particular therapy can be considered. Various handicaps including variability in response reporting, heterogeneity of patient populations, inadequate reporting of failure patterns, causes of death, performance status changes and quality of life hinder interpretation of Phase II data. Nevertheless, Phase II studies have defined prognostic groups, beneficial changes in performance status and have helped formulate novel management approaches. Targeting particular prognostic groups, investigating dose-intensive regimens with haemopoietic growth-factor support and novel combined-modality approaches have all been generated through Phase II investigations.
CitationTreatment evaluation of combined modality therapy: 'what can we obtain today from phase II trials?'. 1994, 10 Suppl 1:S117-33 Lung Cancer
- Combined radiation and chemotherapy for unresectable non-small cell lung carcinoma.
- Authors: Bleehen NM, Ball D, Belani CP, Bishop J, Douillard JY, Cox JD, Johnson DH, Le Chevalier T, Saunders MI, Shaw E
- Issue date: 1994 Mar
- [Cancer of the lung. New perspectives in medical treatment].
- Authors: Gallo Curcio C
- Issue date: 1989 Jul-Dec
- Combined modality therapy for early stage operable and locally advanced potentially resectable non-small cell lung carcinoma.
- Authors: Clark JI, Albain KS
- Issue date: 2001
- [What is to be expected from population studies in relation to clinical trials?].
- Authors: Quoix E
- Issue date: 2006 Feb
- Endpoints in phase II trials for advanced non-small cell lung cancer.
- Authors: Mandrekar SJ, Qi Y, Hillman SL, Allen Ziegler KL, Reuter NF, Rowland KM Jr, Kuross SA, Marks RS, Schild SE, Adjei AA
- Issue date: 2010 Jan